Solu Therapeutics
PrivateLast Round
Series A
Apr 9, 2025
Est. Valuation
$100M
Total Funding Raised
$72M
Company Overview
Solu Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series A round in April 2025.
Solu Therapeutics is a biotechnology company that develops a cytotoxicity-targeting chimera platform designed to eliminate disease-driving cells, providing oncology therapeutics that help reduce the risk of inflammatory and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Solu Therapeutics Comparables
Compare Solu Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Taran Therapeutics, Inc. | 83% | |
| Immune-Onc Therapeutics | 76% | |
| OncoPrecision | 74% |
For institutional investors. Book with your work email.
Solu Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 9, 2025 | ||||
| Seed | Aug 1, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Solu Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hengdian Group Capital | Series A |
| A. M. Pappas & Associates | Series A |
| DCVC Bio | Series A, Seed |
| Santé Ventures | Series A, Seed |
| Alexandria Venture Investments | Series A, Seed |
| Astellas Venture Management | Series A, Seed |
| The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2026
Monthly visitors increased 53% MoM.
- Jun 16, 2025
Enda Moran appointed as the new Chief Operating Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 4, 2026
Solu Therapeutics, Inc. presents initial Phase 1 results for STX-0712 and new preclinical data on STX-0640 in two oral presentations at the 68th American Society of Hematology (ASH) Annual Meeting in Louisiana from Dec 12th–15th '26.
- attends_eventNov 4, 2026
Solu Therapeutics, Inc. plans to present initial Phase 1 results from STX-0712 and new preclinical data on STX-0640 in two oral presentations at the 2026 ASH Annual Meeting in Louisiana in Dec '26.
For institutional investors. Book with your work email.
Solu Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Solu Therapeutics's valuation, stock price, and market status.
Is Solu Therapeutics a public or private company?
Solu Therapeutics is a private company.
What is the current stock price of Solu Therapeutics?
Solu Therapeutics is a private company, so its shares have no public market price. Caplight tracks Solu Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Solu Therapeutics worth (valuation)?
Solu Therapeutics's valuation is estimated at $100.0M based on funding round data.
Can I buy Solu Therapeutics stock?
Solu Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Solu Therapeutics's last funding round?
Solu Therapeutics's most recent funding round was Series A on April 9, 2025.
Who are the main investors in Solu Therapeutics?
Key investors in Solu Therapeutics include Santé Ventures, Longwood Fund, Santé Ventures.
Will Solu Therapeutics IPO soon?
No public IPO plans have been announced for Solu Therapeutics.
How can I track Solu Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Solu Therapeutics's shares on secondary markets.